Brief: ARS Pharmaceuticals To Present Positive Clinical Efficacy Data For Neffy At 2024 Aaaai Annual Meeting
05/02/2024 14:03
Feb 5 (Reuters) - ARS Pharmaceuticals Inc SPRY.O :
* ARS PHARMACEUTICALS TO PRESENT POSITIVE CLINICAL EFFICACY
DATA
FOR NEFFY® (EPINEPHRINE NASAL SPRAY) AT 2024 AAAAI ANNUAL
MEETING
* ARS PHARMACEUTICALS - ON TRACK TO REPORT TOPLINE RESULTS
IN Q1
2024 FROM REPEAT DOSE STUDY OF NEFFY UNDER NASAL ALLERGEN
CONDITIONS REQUESTED BY FDA
* ARS PHARMACEUTICALS - ON TRACK TO REPORT TOPLINE RESULTS
IN
Q12024 FROM REPEAT DOSE STUDY OF NEFFY UNDER NASAL ALLERGEN
CONDITIONS REQUESTED BY FDA
Source text for Eikon: ID:nGNX4nkj5B
Further company coverage: SPRY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle